<b>The phase 2b COPERNICUS study of subcutaneous amivantamab with lazertinib as first-line treatment, or with chemotherapy as second-line treatment, for </b><b><i>EGFR</i></b><b>-mutated non-small cell lung cancer: A Vodcast</b>
media
posted on 2025-10-02, 08:04 authored by Adis journals on behalf of:, Balazs Halmos, Narjust Florez, Sarah Goldberg, Wade Iams, Xiuning Le, Ticiana Leal, Danny Nguyen, Luis E. Raez, Jonathan W. Riess, Joshua Sabari, David Bjork, Nichelle Stigger, Yichuan Xia, Paul Cifuentes, Denise D’Andrea, Farah Shanoon, Andy L. Johnson, Melissa L. Johnson<p dir="ltr"><b>Article full text</b></p><p dir="ltr">The above Podcast represents the opinions of the authors. For a full list of declarations, including funding and author disclosure statements, and copyright information, please see the full text online (see “read the peer-reviewed publication” opposite).</p>
History
Related Materials
- 1.
